[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ebv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ebv":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,53,85,115,142,169,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":4,"leadSponsor":49,"locationsCount":52},"100133849","the-natural-history-of-severe-viral-infections-and-characterization-of-immune-defects-in-patients-without-known-immunocompromise-100133849",false,"NCT01011712","The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise","The Natural History of Severe Viral Infections and Characterization of Immune Defects","* INCLUSION CRITERIA:\n\n(Participants)\n\nParticipants must meet all the following inclusion criteria in order to participate in this study:\n\n1. Children or adults (regardless of age) with a definitively diagnosed severe or unusual viral infection, including but not limited to infections caused by herpesviruses (HSV-1, HSV-2, CMV, EBV, VZV, HHV-6, HHV-7, HHV-8), human papillomavirus (e.g., severe recalcitrant warts), adenovirus, calicivirus (e.g. norovirus), polyomavirus (such as JC virus and BK virus), or influenza virus. Viral infections that would be considered opportunistic-like , such as herpesvirus esophagitis, herpesvirus encephalitis, CMV colitis, or progressive multifocal leukoencephalopathy (caused by the JC polyoma virus) will be of particular interest in this protocol.\n\n   OR\n\n   Children or adults with a well-documented prior, severe, persistent, or treatment-refractory viral infection(s), who have clinically recovered from the viral infection.\n2. Ongoing care by a referring physician.\n3. Willingness to allow storage of blood and tissue samples for future analyses.\n\n(Relatives)\n\nRelatives (2 years or above) may be recruited and enrolled to improve interpretation of genetic results, to expand the phenotype of the suspected or confirmed inborn error of immunity in the proband with severe viral infection, and to understand the co-factors in affected and\u002For unaffected family members that may influence variable expressivity and penetrance of viral infections in inborn errors of immunity.\n\n1. Males and females will be accepted.\n2. Relatives may either be healthy or have features concerning for an inborn error of immunity including, but not limited to, autoimmunity, severe atopy, other forms of immune-dysregulation, or severe or unusual infections. While the enrolled proband must have a current or prior severe or unusual viral infection, family members who are suspected to have an inborn error of immunity do not need to have a history of severe or unusual viral infection in the presence of other features suspicious for inborn errors of immunity.\n3. Adult relatives or the guardians of minor relatives must be willing and capable of providing informed consent after review of protocol procedures that are described in the consent form with an appropriate study team member.\n4. Participating relatives agree to have blood stored for future studies of the immune system.\n\nEXCLUSION CRITERIA:\n\nParticipants meeting any of the following exclusion criteria at baseline will be excluded from study participation:\n\n1. Patients with previously diagnosed conditions associated with acquired or iatrogenic immunodeficiency and\u002For immunosuppresion (e.g., a history of HIV infection, a positive test for HIV, chemotherapy or high dose glucocorticoids). Patients on immunosuppression and\u002For immunomodulatory therapy for the treatment of conditions that may be attributable to an underlying inborn error of immunity may be included in the study at the discretion of the PI or their designee.\n2. Women who are pregnant.\n3. Any condition or major comorbidity that the study investigators believe will compromise the patient's ability to comply with the requirements of the study.","ALL","2 Years","100 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","Background:\n\n* Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore throats, chicken pox, and the flu are caused by different viruses. Usually, these illnesses last only few days or, at most, a few weeks. Some virus infections like influenza are cleared from the body, and others such as the chicken pox virus remain in the body in an inactive state. However, some people may become quite ill when they are infected with a particular virus, possibly because part of their immune system does not respond properly to fight the virus.\n* Researchers have discovered some reasons why a person may not be able to clear an infection caused by a virus. Some persons have changes in the genes that involve the immune system that result in the inability to properly control infection with a particular virus. Identifying changes in genes that involve the immune system should help scientists better understand how the immune system works to protect people from infection and may help develop new therapies.\n\nObjectives:\n\n* To study possible immune defects that may be linked to a particular severe viral infection.\n* To determine if identified immune defects are genetic in origin.\n\nEligibility:\n\n* Individuals of any age who have or have had a diagnosis of a virus infection that physicians consider to be unusually severe, prolonged, or difficult to treat.\n* Relatives of the participants with a severe viral infection may also participate in the study. We will use their blood and\u002For skin specimens to try to determine if identified immune defects are hereditary.\n\nDesign:\n\n* Prior to the study, the participant's doctor will give researchers the details of the infection, along with medical records for review. Eligible participants will be invited to the NIH Clinical Center for a full evaluation as an outpatient or inpatient.\n* At the Clinical Center, participants will be treated with the best available therapy for the particular viral infection, and researchers will monitor how the infection responds to the treatment.\n* Researchers will take intermittent blood samples and conduct other tests (such as skin biopsies) to evaluate the immune system. - During and after the illness, researchers will conduct follow-up visits to determine the course of infection and response to therapy.",[25,26,27,28,29],"EBV","HSV","VZV","HPV","CMV",[31,32,33,34,35,36,37,38,39,40,41],"Genetics","Virus","Defense","Immunity","Immunodeficiency","Natural History","Respiratory Viruses","Herpesvirus","Cytomegalovirus","Human Papillomavirus","Adenovirus","RECRUITING","2026-06-17",{"date":45,"type":46},"2026-06-18","ACTUAL",{"date":48,"type":46},"2009-10-01",{"name":50,"class":51},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":52},"100585878","phase-1-epstein-barr-virus-ebv-ghglgp42-ferritin-nanoparticle-vaccine-with-or-without-gp350-ferritin-in-healthy-adults-with-or-without-ebv-infection-100585878","NCT06908096","Epstein-Barr Virus (EBV) gH\u002FgL\u002Fgp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection","Phase 1 Study of the Safety of an Epstein-Barr Virus (EBV) gH\u002FgL\u002Fgp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. 18 to 29 years old.\n2. Able to provide informed consent.\n3. Willingness to allow storage of blood and saliva for future research.\n4. In good general health as evidenced by medical history, physical examination, and laboratory screening results.\n5. Participant is willing to forgo receipt of a licensed, live vaccine in the 30 days preceding each dose of vaccine or in the 30 days following each dose of vaccine. Any FDA-approved inactivated, subunit, or replication-defective vaccine (such as COVID-19, influenza, tetanus, etc.) can be used \\>=14 days before or \\>=14 days after administration of the study vaccine.\n6. Participants of reproductive potential who are sexually active with a partner who can impregnate them: use of highly effective continuous contraception for at least 30 days prior to Day 0 and agreement to continue use until 60 days after the last dose of vaccine.\n\nContraceptive requirements: Because the effects of EBV gH\u002FgL\u002Fgp42-FNP and EBV gp350-ferritin vaccines on the developing human fetus are unknown, sexually active participants of childbearing potential must agree to use highly effective contraception as outlined below before study entry and until 60 days after the last dose of vaccine. Participants of childbearing potential must have a negative pregnancy test before receiving each dose of the EBV gH\u002FgL\u002Fgp42-FNP vaccine. During the course of the study, if a participant becomes pregnant or suspects they are pregnant, then they should inform the study staff and their primary care physician immediately.\n\nAcceptable forms of contraception are:\n\n* Intrauterine device (IUD) or equivalent.\n* Hormonal contraceptive (eg, consistent, timely, and continuous use of contraceptive pill, patch, ring, implant, or injection that has reached full efficacy prior to dosing). If the participant uses a contraceptive pill, patch, or ring, then a barrier method (eg, internal\u002Fexternal condom, cap, or diaphragm plus spermicide) must also be used at the time of potentially reproductive sexual activity.\n* A stable, long-term monogamous relationship with a partner who does not pose any potential pregnancy risk, eg, has undergone a vasectomy at least 6 months prior to the first dose of vaccine or is of the same sex as the participant.\n* A hysterectomy and\u002For a bilateral tubal ligation or bilateral oophorectomy.\n\nAcceptable forms of contraception for participants who can impregnate a partner include one of the following:\n\n* External condom plus spermicide, used during sexual intercourse, even if the partner uses a contraceptive pill, patch, or ring.\n* A vasectomy completed at least 6 months before the first dose of vaccine.\n* Continuously and completely abstaining from sexual intercourse with a partner of childbearing potential from the first dose of vaccine until 30 days after the last dose.\n\nAcceptable contraception for partners of childbearing potential of participants who can impregnate them include one of the following:\n\n* IUD or equivalent.\n* Hormonal contraceptive (eg, pill, patch, ring, implant, or an injection used consistently and that has reached full effect prior to the first dose of vaccine).\n* Hysterectomy and\u002For a bilateral tubal ligation or bilateral oophorectomy.\n\nLaboratory Criteria within 30 days or less prior to enrollment:\n\n1. Hemoglobin within institutional normal limits or if not, then assessed and deemed not clinically significant by PI or designee\n2. White blood cell count and differential either within institutional normal reference range or if not then assessed and deemed not clinically significant by PI or designee\n3. Total lymphocyte count (lymphocyte absolute) \\> 800 cells\u002FmicroL\n4. Platelet count equal to 125,000-500,000\u002FmicroL\n5. Alanine aminotransferase \\\u003C1.25 x upper limit of normal (ULN)\n6. Serum IgG \\>600 mg\u002FdL\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnant, breastfeeding, or planning to become pregnant while participating through 60 days after the last dose of vaccine.\n2. Participant has received any of the following:\n\n   1. More than 10 days of systemic immunosuppressive medications (\\>=10 mg prednisone dose or its equivalent) or cytotoxic medication within the 30 days prior to first dose of vaccine or immunomodulating therapy within 180 days prior to first dose of vaccine.\n   2. Blood products, including immunoglobulin products, within 120 days prior to first dose of vaccine.\n   3. Investigational research agents within 30 days prior to first dose or planning to receive investigational products while on study.\n   4. Allergy treatment with antigen injections, unless on a maintenance schedule of shots no more frequently than once per month.\n   5. Prior participant in an EBV vaccine clinical trial.\n3. Participant has any of the following:\n\n   1. Febrile illness within 14 days of the first dose of vaccine.\n   2. Body habitus such that it is difficult to confirm location of the deltoid muscle for safe intramuscular injection.\n   3. History of serious reactions to vaccines.\n   4. Hereditary, acquired, or idiopathic forms of angioedema.\n   5. Idiopathic urticaria within the past year.\n   6. Asthma that is not well-controlled or required emergent care, urgent care, hospitalization, or intubation during the past 2 years or that requires the use of oral or intravenous steroids.\n   7. Diabetes mellitus type 1 or type 2, excluding a history of gestational diabetes.\n   8. Clinically significant autoimmune disease or immunodeficiency.\n   9. Hypertension that is not well-controlled.\n   10. Thyroid disease that is not well-controlled.\n   11. Bleeding disorder diagnosed by doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions).\n   12. Significant bruising or bleeding difficulties with intramuscular injections or blood draws.\n   13. Malignancy that is active or treated malignancy for which there is no reasonable assurance of sustained cure or malignancy that is likely to recur during the study period.\n   14. Seizure disorder other than a history of 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the past 3 years.\n   15. Asplenia, functional asplenia, or any condition resulting in absence or removal of the spleen.\n   16. History of Guillain-Barre Syndrome.\n   17. Alcohol or drug abuse or addiction.\n   18. HIV infection.\n4. Any medical, psychiatric, or social condition that, in the judgement of the investigator, is a contraindication to protocol participation or impairs the participant's ability to give informed consent.",true,"18 Years","29 Years",{"count":64,"type":21},750,"INTERVENTIONAL",[67],"PHASE1","Background:\n\nEpstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population. Mono can be serious, and it can lead to severe illnesses like cancer and autoimmune diseases. Researchers want to test vaccines that may help prevent EBV and associated diseases.\n\nObjective:\n\nTo test two EBV vaccines: EBV gH\u002FgL\u002Fgp42-ferritin and EBV gp350-ferritin.\n\nEligibility:\n\nHealthy EBV-negative or EBV-positive people aged 18 to 29.\n\nDesign:\n\nParticipants will be screened. They will have a physical examination. They will give blood and saliva samples.\n\nThey will receive 3 doses of the study vaccine as an injection in the shoulder muscle. They will get either one vaccine or a combination of both vaccines.\n\nParticipants will get their first dose of the vaccine at visit 1, the second dose about 30 days later, and the final dose about 90 days after that.\n\nParticipants will be given a memory aid so they can record any symptoms and side effects between visits. This can be done either on paper or online through a link that is emailed to them.\n\nThere are 6 required in-person visits. There are also 2 optional visits. In between the in-person visits are 7 telehealth visits or phone calls. Each visit may take up to 4 hours.\n\nThe study will last for about 17 months. Participants will have the option of staying in the study for an additional year.",[25,70,71,72],"Epstein-Barr Virus Infection","Infectious Mononucleosis","Mono",[71,74,75,25,72,76],"Neutralizing Antibody","Vaccine","Immune Response","2026-05-15",{"date":79,"type":46},"2026-05-18",{"date":81,"type":46},"2025-05-29",{"date":83,"type":21},"2028-10-01",{"name":50,"class":51},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":60,"sex":16,"minAge":61,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":65,"phases":95,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100635816","phase-1-mrna-vaccine-targeting-epstein-barr-virus-ebv-in-healthy-young-adults-100635816","NCT07557602","mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults","A Phase 1, Dose Escalation, Placebo-Controlled, Adaptive-Design Study to Evaluate the Safety and Immunogenicity of VXCO-102, a mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults","Inclusion Criteria:\n\n* Aged 18 to 25 years, inclusive\n* Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment\n\nExclusion Criteria:\n\n* Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation\n* Likely or confirmed myocarditis or pericarditis\n* Prior receipt of an investigational EBV vaccine\n* Prior receipt of a licensed vaccine within 56 days prior to Day 1\n* Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study.\n* For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study\n\nNote: Other inclusion and exclusion criteria apply.","25 Years",{"count":94,"type":21},45,[67],"This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.",[25],[25,99,100,101,102],"vaccine","mRNA","first in human","Epstein-Barr virus","NOT_YET_RECRUITING","2026-04-22",{"date":106,"type":46},"2026-04-29",{"date":108,"type":21},"2026-05-04",{"date":110,"type":21},"2027-08-31",{"name":112,"class":113},"Vaccine Company, Inc.","INDUSTRY",2,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":65,"phases":125,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":52},"100621370","phase-2-golidocitinib-combined-with-selinexor-for-caebvd-100621370","NCT07369739","Golidocitinib Combined With Selinexor for CAEBVD","Golidocitinib Combined With Selinexor for the Treatment of Chronic Active Epstein-Barr Virus Disease (CAEBVD): A Multicenter, Prospective, Single-arm Clinical Study","Inclusion Criteria:\n\n1. CAEBVD diagnosed in accordance with the Consensus on the Diagnosis and Treatment of Chronic Active Epstein-Barr Virus Disease (2025 Edition).\n2. Aged ≥ 18 years and ≤ 70 years, regardless of gender.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n4. Before the initiation of the study, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); total bilirubin ≤ 2 × ULN; serum creatinine ≤ 1.5 × ULN.\n5. Routine blood test: absolute neutrophil count ≥ 1 × 10#\u002FL; platelet count ≥ 50 × 10#\u002FL; hemoglobin ≥ 60 g\u002FL.\n6. Coagulation function test requirements: international normalized ratio (INR) ≤ 2.0; prothrombin time (PT) ≤ 1.5 × ULN.\n7. Women of childbearing potential must have a negative pregnancy test result, and be willing to take effective contraceptive measures during the trial period and for ≥ 12 months after the last dose; all male subjects must take contraceptive measures during the trial period and for ≥ 6 months after the last dose.\n8. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Evidence of EBV-associated hematological diseases or malignancies, such as hemophagocytic lymphohistiocytosis, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, non-Hodgkin's lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, and gastric cancer.\n2. Having received any of the following treatments: prior treatment with any JAK inhibitor; administration of any investigational drug within 12 weeks prior to the first dose of the study drug; concurrent enrollment in another clinical study.\n3. A history of other primary malignancies within 5 years prior to the first dose of the study drug, excluding locally curable malignancies that have received curative treatment (e.g., basal or squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast).\n4. A history of organ transplantation (e.g., liver transplantation, kidney transplantation).\n5. Planned hematopoietic stem cell transplantation during the study period.\n6. Active hepatitis B (defined as positive hepatitis B surface antigen \\[HBsAg\\] at screening, or a peripheral blood hepatitis B virus DNA titer \\> 1×10³ copies\u002FmL); active hepatitis C (defined as positive anti-hepatitis C virus antibody \\[HCV-Ab\\] and HCV-RNA at screening); positive serum HIV antigen or antibody; a history of syphilis.\n7. Having undergone major surgery within 4 weeks prior to the first dose, or anticipating the need for major surgery during the study period.\n8. Pregnant or lactating women.\n9. A history of severe mental illness or drug abuse.\n10. Uncontrolled infections (including pulmonary infection, intestinal infection); active major visceral hemorrhage (including gastrointestinal bleeding, alveolar hemorrhage, intracranial hemorrhage).\n11. Hypersensitivity to the components of the study drug, or a history of severe allergic diathesis.\n12. Patients who are unable to comply with the requirements during the trial and\u002For follow-up phase.","70 Years",{"count":124,"type":21},28,[126,127],"PHASE2","PHASE3","This study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.",[130,25,131],"Lymphohistiocytosis","CAEBV","2026-01-17",{"date":134,"type":46},"2026-01-27",{"date":136,"type":46},"2026-01-01",{"date":138,"type":21},"2028-01-01",{"name":140,"class":141},"Beijing Friendship Hospital","OTHER",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":65,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":52},"100209752","phase-2-a-study-to-assess-safety-and-feasibility-of-direct-infusions-of-donor-derived-virus-specific-t-cells-in-recipients-of-hematopoietic-stem-cell-transplantation-with-post-transplant-viral-infections-using-the-cytokine-capture-system-100209752","NCT02007356","A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®","A Phase I\u002FII Single-center Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®","CCS","Inclusion Criteria:\n\n* Adults \\> 18 years of age\n* Undergone allogeneic HSCT\n* Written informed consent\n* Patients with treatment refractory infections with adenovirus, cytomegalovirus (CMV) or Epstein-Barr virus (EBV) will be included in case of fulfilling following criteria:\n\nPatient with Adenovirus Infection:\n\n1. Antiviral treatment with cidofovir for at least 7 days\n\n   * no virus load decrease ( ≤ 1 log) or virus load increase on treatment for at least 7 days or\n   * cluster of differentiation 3 (CD3) + cells \\\u003C 300\u002FµL on treatment for at least 7 days\n2. Or if antiviral treatment is contraindicated\n\nPatient with EBV:\n\n1\\. After receipt of at least one anti-cluster of differentiation 20 antigen (CD20)-antibody treat-ment (375 mg\u002Fm2)\n\n* No Virus load decrease (≤ 1 log) or virus load increase 7 days after receipt of treatment or\n* CD3+ cells \\\u003C 300\u002FµL 7 days after receipt of treatment or\n* Clinical progression\n\nPatient with CMV:\n\n1. Antiviral treatment with ganciclovir or foscavir for 14 days\n\n   \\- No Virus load decrease (≤ 1 log) or virus load increase on day 14\n2. Or if \\> 2 recurrences despite antiviral treatment with ganciclovir or foscavir for 14 days and CD3+ cells \\\u003C 300\u002FµL\n3. Or if antiviral treatment is contraindicated -\n\nPatient Exclusion Criteria:\n\n* graft-versus-host disease (GVHD) \\> grade 2 at the time point of planned infusion\n* Known allergy to iron-dextran or murine antibodies","65 Years",{"count":152,"type":21},30,[126],"To assess the feasibility of donor-derived interferon (IFN)-γ positive select-ed virus-specific T-cells using the cytokine capture system® (CCS) and the safety of subsequent infusion in recipients of hematopoietic stem cell transplantation (HSCT) with treatment refractory post-transplant viral infections. The CCS has already been successfully used in clinical studies in Germany and United Kingdom (UK).",[156,25,157,158,159],"Adenovirus Infection","Cytomegalovirus Infections","Cytokine Capture System","Allogenic Disease","2025-03-19",{"date":162,"type":46},"2025-03-20",{"date":164,"type":46},"2014-12",{"date":166,"type":21},"2026-12",{"name":168,"class":141},"University Hospital, Basel, Switzerland",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":122,"enrollmentInfo":175,"targetDuration":4,"studyType":65,"phases":177,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100573914","early-phase-1-ksd-101-therapy-for-standard-treatment-failed-ebv-associated-nasopharyngeal-carcinoma-an-exploratory-clinical-trial-100573914","NCT06752473","KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial","Inclusion Criteria:\n\n1. Patients or their legal guardian voluntarily participate and sign an informed consent form.\n2. Female or emale patients aged 18-70 years (inclusive of the cut-off value) on the date of signing the informed consent.\n3. Nasopharyngeal carcinoma confirmed by pathological tissue examination and EBER-positive in tumor tissue by in situ hybridization (ISH or FISH).\n4. Nasopharyngeal carcinoma with localized recurrence or localized recurrence with systemic metastasis, or primary metastatic nasopharyngeal carcinoma unsuitable for localized or radical treatment, for which there is no effective treatment and which is seriously life-threatening.\n5. At least one measurable lesion according to RECIST v1.1 criteria.\n6. An Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.\n7. Have criteria for single or venous blood collection and have no other contraindications to cell collection.\n8. Patients' laboratory findings are compatible:\n\n(1)Blood routine: neutrophils ≥ 1.5×10\\^9\u002FL, hemoglobin ≥ 90g\u002FL, platelets ≥ 100×10\\^9\u002FL.\n\n(2)Liver function: ALT, AST ≤ 3 × ULN and total bilirubin ≤ 1.5 × ULN. (3)Renal function: creatinine ≤ 1.5 × ULN. (4)Cardiac function: left ventricular ejection fraction (LVEF) ≥ 40%. (5)Coagulation function: fibrinogen ≥ 1.0g\u002FL, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN, prothrombin time (PT) ≤ 1.5 × ULN.\n\n9.Patients' corresponding lymph node region can accommodate subcutaneous injections.\n\n10.Expected survival ≥ 3 months.\n\nExclusion Criteria:\n\n1. Patients receiving any anti-tumor therapy such as chemotherapy, radiotherapy, immunosuppressive therapy, etc. within 4 weeks prior to mono-collection.\n2. Women who are pregnant (positive urine\u002Fblood pregnancy test), breastfeeding, or men or women who are planning to conceive within the last 1 year.\n3. Active hepatitis B (HbsAg or HbcAb positive and HBV DNA ≥100 IU\u002FmL), active hepatitis C (HCV antibody positive and peripheral blood HCV RNA positive); human immunodeficiency virus (HIV) antibody positive; syphilis test positive.\n4. Patients with central nervous system pathology (e.g., cerebral edema, need for hormonal intervention, or progression of brain metastases).\n5. Patients with uncontrollable infectious disease within 4 weeks prior to enrollment, or with active tuberculosis or on anti-tuberculosis therapy. (\\\u003C CTCAE grade 2 genitourinary infections and upper respiratory tract infections, except EBV infections).\n6. Patients have a serious underlying disease (cardiovascular disease, respiratory disease, renal insufficiency, coagulation abnormality, autoimmune disease or immunodeficiency disease, etc.).\n7. Other active malignant tumors within the past 3 years, unless they are curable tumors and have been significantly cured, such as basal or squamous cell carcinoma, carcinoma in situ of the uterine cervix or breast.\n8. Subjects who have undergone major surgery or severe trauma within 4 weeks prior to enrollment or are expected to require major surgical intervention (i.e., surgery requiring the assistance of endotracheal anesthesia) during the study period.\n9. Patients have received a prophylactic live or live attenuated vaccine within 4 weeks prior to screening.\n10. Patients have participated in another clinical study within 4 weeks prior to screening.\n11. Patients with a prior history of severe drug allergy, or penicillin allergy.\n12. Patients have substance abuse\u002Faddiction. 13,Patients have other conditions that, in the judgment of the investigator, make enrollment inappropriate.",{"count":176,"type":21},10,[178],"EARLY_PHASE1","The main purpse of this study is to evaluate the safety of KSD-101 in patients with EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated Nasopharyngeal Carcinoma.",[181,25],"Nasopharyngeal Carcinoma (NPC)","2024-12-27",{"date":184,"type":46},"2024-12-30",{"date":186,"type":21},"2025-01-31",{"date":188,"type":21},"2027-02-28",{"name":190,"class":141},"Kousai Bio Co., Ltd.",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":150,"enrollmentInfo":198,"targetDuration":4,"studyType":65,"phases":200,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":52},"100553871","a-study-on-efficacy-and-safety-of-ink-cells-for-caebv-ebv-hlh-after-allo-hsct-100553871","NCT06491719","A Study on Efficacy and Safety of iNK Cells for CAEBV \u002FEBV-HLH After Allo-HSCT","A Study on Efficacy and Safety of iNK Cell Infusion in Patients With Chronic Active Epstein-Barr Virus Infection (CAEBV) and Epstein Barr Virus-induced Haemophagocytic Lymphohistiocytosis (EBV-HLH) After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Patients with CAEBV or EBV-HLH who are eligible for allogeneic hematopoietic stem cell transplantation meet one of the following criteria:\n\n   ①EBV-DNA (PBMC or plasma) was still more than 103 before transplantation；②Positive for Cerebrospinal fluid EBV-DNA；\n\n   ③Abnormal phenotypic lymphocytes could still be detected in bone marrow immunotyping；\n\n   ④Measurable EBV-related lesions on imaging；\n2. ≤65 years，ECOG :0-2；\n3. Cardiac EF≥40%, creatinine clearance ≥50%; aminotransferase（ALT\u002FAST）\\\u003C200U\u002FL。；\n4. In patients with HLH, HLH efficacy ≥Partial Response after prior treatment is required；\n5. Estimated survival time is longer than three months；\n6. Agree to sign the Informed Consent Form。\n\nExclusion Criteria:\n\n1. Patients with evidence of grade II or more serious heart disease according to the New York Heart Association (NYHA) score (including Grade II) ; Clear diagnosis of cirrhosis；\n2. Active infections other than EBV that have not yet been controlled；\n3. Positive for hepatitis B virus or hepatitis C virus；\n4. Active massive hemorrhage of internal organs (including gastrointestinal hemorrhage, alveolar hemorrhage, intracranial hemorrhage, etc.)；\n5. Also participation in other interventional clinical studies within 4 weeks",{"count":199,"type":21},15,[201],"NA","To evaluate the efficacy and safety of iNK cells infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)",[204,25,205],"CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome","Hemophagocytic Lymphohistiocytoses","2024-07-09",{"date":208,"type":46},"2024-07-11",{"date":210,"type":21},"2024-07-15",{"date":212,"type":21},"2026-07-15",{"name":140,"class":141}]